A Phase I/II Study of Concurrent Ipilimumab and Dabrafenib in Unresectable Stage III or Stage IV Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 03 Mar 2017
Price : $35 *
At a glance
- Drugs Dabrafenib (Primary) ; Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 20 Jan 2017 Status changed from active, no longer recruiting to discontinued as BMS withdrew support and required this trial to stop enrolling
- 03 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 03 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.